SG11202005237SA - 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer - Google Patents

5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Info

Publication number
SG11202005237SA
SG11202005237SA SG11202005237SA SG11202005237SA SG11202005237SA SG 11202005237S A SG11202005237S A SG 11202005237SA SG 11202005237S A SG11202005237S A SG 11202005237SA SG 11202005237S A SG11202005237S A SG 11202005237SA SG 11202005237S A SG11202005237S A SG 11202005237SA
Authority
SG
Singapore
Prior art keywords
pyrazolo
difluorophenyl
pyrazol
pyrrolidin
treating cancer
Prior art date
Application number
SG11202005237SA
Other languages
English (en)
Inventor
Kollol Pal
Stephane Ciblat
Vincent Albert
Nicolas Bruneau-Latour
Jonathan Boudreault
Original Assignee
Pyramid Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyramid Biosciences Inc filed Critical Pyramid Biosciences Inc
Publication of SG11202005237SA publication Critical patent/SG11202005237SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202005237SA 2017-12-15 2018-12-12 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer SG11202005237SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599490P 2017-12-15 2017-12-15
PCT/US2018/065187 WO2019118584A1 (en) 2017-12-15 2018-12-12 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
SG11202005237SA true SG11202005237SA (en) 2020-07-29

Family

ID=65139120

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005237SA SG11202005237SA (en) 2017-12-15 2018-12-12 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Country Status (26)

Country Link
US (4) US11230546B2 (de)
EP (2) EP3724191B9 (de)
JP (1) JP7321183B2 (de)
KR (1) KR102738182B1 (de)
CN (1) CN111819179B (de)
AU (1) AU2018383571B2 (de)
CA (1) CA3084814A1 (de)
DK (2) DK4053128T3 (de)
EA (1) EA202091475A1 (de)
ES (2) ES2908773T3 (de)
FI (1) FI4053128T3 (de)
HR (2) HRP20220464T1 (de)
HU (2) HUE059313T2 (de)
IL (1) IL275059B2 (de)
LT (2) LT3724191T (de)
MX (1) MX2020006293A (de)
PL (2) PL4053128T3 (de)
PT (2) PT3724191T (de)
RS (1) RS66124B1 (de)
SA (1) SA520412192B1 (de)
SG (1) SG11202005237SA (de)
SI (2) SI3724191T1 (de)
SM (1) SMT202400435T1 (de)
TW (1) TWI848925B (de)
WO (1) WO2019118584A1 (de)
ZA (2) ZA202003483B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486276B2 (en) 2017-12-15 2025-12-02 Pyramid Biosciences, Inc. 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
CN111718350B (zh) * 2019-03-19 2021-04-13 华中师范大学 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
JP7209415B2 (ja) * 2019-03-19 2023-01-20 セントラル チャイナ ノーマル ユニバーシティ ピラゾロピリミジン化合物、医薬組成物、及びその使用
CN111848626B (zh) * 2019-04-30 2021-11-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
JP7767301B2 (ja) * 2020-04-15 2025-11-11 ピラミッド バイオサイエンシズ インコーポレイテッド チロシン受容体キナーゼ阻害剤を調製する方法
CN114437077B (zh) * 2020-11-04 2024-01-30 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
KR102541026B1 (ko) * 2020-11-11 2023-06-12 주식회사 한독 Trk 억제제 화합물의 제조 방법
CA3201690A1 (en) * 2020-12-15 2022-06-23 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
KR20250056969A (ko) * 2022-09-07 2025-04-28 수저우 랑루이 바이오파마슈티컬 씨오 엘티디 마크로시클릭 이미다조[1,2-b]피리다진 유도체 및 이의 제조 방법과 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP2300469B1 (de) 2008-05-13 2015-06-24 Novartis AG Kondensierte stickstoff enthaltende heterozyklen sowie zusammensetzungen davon zur verwendung als kinase inhibitoren
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8865726B2 (en) 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
IN2014DN07384A (de) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
US20140288043A1 (en) 2013-03-19 2014-09-25 Genentech, Inc. Pyrazolopyridine compounds
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
FR3029769A1 (fr) * 2014-12-10 2016-06-17 Tornier Sa Kit pour une prothese d'epaule
ES2983908T3 (es) * 2014-12-15 2024-10-28 Cmg Pharmaceutical Co Ltd Compuestos heteroarílicos de anillo condensado y su uso como inhibidores de TRK
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
JP6475084B2 (ja) 2015-05-21 2019-02-27 臼井国際産業株式会社 トルクセンサ用シャフトの製造設備およびその製造方法
DE102016219374B4 (de) 2016-10-06 2018-06-14 Siemens Aktiengesellschaft Langzeitstabile und stoffschlüssige Strompfadverbindung für Nieder-, Mittelspannungs- und/oder Hochspannungsanlagen bzw. –Schaltgeräte mittels Nanomaterialien
RS66124B1 (sr) 2017-12-15 2024-11-29 Biohaven Therapeutics Ltd Derivati 5-(2-(2,5-difluorofenil)pirolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina i srodna jedinjenja kao inhibitori trk kinaze za lečenje kancera
CN112398593B (zh) 2019-08-13 2024-08-16 上海朗帛通信技术有限公司 一种被用于无线通信的节点中的方法和装置
JP7767301B2 (ja) 2020-04-15 2025-11-11 ピラミッド バイオサイエンシズ インコーポレイテッド チロシン受容体キナーゼ阻害剤を調製する方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486276B2 (en) 2017-12-15 2025-12-02 Pyramid Biosciences, Inc. 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

Also Published As

Publication number Publication date
CN111819179B (zh) 2023-09-01
EP4053128B1 (de) 2024-08-21
PT4053128T (pt) 2024-10-15
US20240246976A1 (en) 2024-07-25
ZA202205900B (en) 2023-11-29
ES2908773T3 (es) 2022-05-03
TW201936194A (zh) 2019-09-16
CN111819179A (zh) 2020-10-23
DK3724191T3 (da) 2022-03-14
IL275059B2 (en) 2023-11-01
JP7321183B2 (ja) 2023-08-04
HUE069285T2 (hu) 2025-02-28
EA202091475A1 (ru) 2020-09-09
US20220235055A1 (en) 2022-07-28
IL275059B1 (en) 2023-07-01
WO2019118584A1 (en) 2019-06-20
HRP20220464T1 (hr) 2022-05-27
IL275059A (en) 2020-07-30
BR112020011775A2 (pt) 2020-11-17
CA3084814A1 (en) 2019-06-20
TWI848925B (zh) 2024-07-21
PT3724191T (pt) 2022-03-07
SI4053128T1 (sl) 2025-03-31
US11739096B2 (en) 2023-08-29
KR102738182B1 (ko) 2024-12-03
RS66124B1 (sr) 2024-11-29
HRP20241426T1 (hr) 2024-12-20
FI4053128T3 (fi) 2024-10-25
SMT202400435T1 (it) 2025-01-14
SA520412192B1 (ar) 2022-08-11
EP3724191B1 (de) 2022-01-26
EP4053128B8 (de) 2024-10-02
AU2018383571B2 (en) 2023-09-21
LT3724191T (lt) 2022-04-25
PL4053128T3 (pl) 2025-01-27
US12486276B2 (en) 2025-12-02
EP3724191A1 (de) 2020-10-21
SI3724191T1 (sl) 2022-06-30
HUE059313T2 (hu) 2022-11-28
ES2992993T3 (en) 2024-12-20
US20230124248A1 (en) 2023-04-20
KR20200099557A (ko) 2020-08-24
LT4053128T (lt) 2024-11-25
US11230546B2 (en) 2022-01-25
EP4053128A1 (de) 2022-09-07
PL3724191T3 (pl) 2022-04-25
MX2020006293A (es) 2020-12-03
JP2021506954A (ja) 2021-02-22
DK4053128T3 (da) 2024-10-21
US20210094956A1 (en) 2021-04-01
AU2018383571A1 (en) 2020-06-18
ZA202003483B (en) 2023-01-25
EP3724191B9 (de) 2022-05-18

Similar Documents

Publication Publication Date Title
ZA202003483B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL280701A (en) History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds related as PTPN11 (SHP2) inhibitors for cancer treatment
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
IL265918A (en) Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors
HUE052454T2 (hu) CDK4 inhibitorok 2-((5-(1-(3-(metilszulfonil)propil)piperidin-4-il)piridin-2-il)amino)-pirido[2,3-D]pirimidin-7(8H)-on származékok és rokonvegyületek tumorok kezelésére
PT3458456T (pt) Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
NZ598086A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
IL288529A (en) History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
MX394556B (es) Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
HK40029595A (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PT3621966T (pt) Derivados de pirazole[1,5-a]pirimidina como inibidores de cinase jak